Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.60 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.45 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.44 |
| ▸ | KCNK3 known ✓ | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 known ✓ | Q9NPC2 | 1/20 | 0.44 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.59 |
| ▸ | FEN1 | P39748 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30113107 | 1.00 | PARP1 (0.60) | PARP1ERCC5FEN1MEN1KMT2A | |
| SCHEMBL71731 | 0.98 | PARP1 (0.62) | PARP1ERCC5FEN1MEN1KMT2A | |
| SCHEMBL10792354 | 0.85 | PARP1 (0.60) | PARP1ERCC5FEN1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11784628 | 0.82 | ERCC5 (0.61) | PARP1ERCC5FEN1MEN1KMT2A | |
| SCHEMBL11791699 | 0.82 | ERCC5 (0.76) | PARP1ERCC5FEN1MEN1KMT2A | |
| SCHEMBL29962144 | 0.82 | ERCC5 (0.76) | PARP1ERCC5FEN1MEN1KMT2A | |
| SCHEMBL10792681 | 0.80 | PARP1 (0.55) | PARP1ERCC5FEN1MEN1KMT2A | |
| SCHEMBL97933 | 0.80 | ERCC5 (0.62) | PARP1ERCC5FEN1MEN1KMT2A | |
| SCHEMBL4565219 | 0.80 | ERCC5 (0.62) | PARP1ERCC5FEN1MEN1KMT2A | |
| SCHEMBL1712221 | 0.80 | ERCC5 (0.62) | PARP1ERCC5FEN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
| US-11034685-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2021-06-15 | — | — | US | disclosed |
| US-11034686-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2021-06-15 | — | — | US | disclosed |
| US-20200299287-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-09-24 | — | — | US | disclosed |
| US-20200299288-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-09-24 | — | — | US | disclosed |
| US-10723725-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-07-28 | — | — | US | disclosed |
| EP-3074390-B1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2020-07-08 | — | — | EP | disclosed |
| US-20190152965-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2019-05-23 | — | — | US | disclosed |
| US-10233176-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2019-03-19 | — | — | US | disclosed |
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| US-6114582-A | DECYCLIZATION TO FORM A CHEMICAL INTERMEDIATE FOR PRODUCING AN ANTI-OBESITY AGENT AND ANTIDIABETIC AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| EP-0939134-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0924193-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0924194-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5608109-A | AGRICULTURAL AND HORTICULTURAL INSECTICIDE | NIHON NOHYAKU CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0657421-A1 | Hydrazine derivatives and their use as insecticides | NIHON NOHYAKU CO., LTD. (JP) | 1995-06-14 | — | — | EP | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | PARP1 4784/4885GRIN2B 745/4885SLC6A2 4710/4885 |
| US-20200299287-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K6, MAP3K5, MERTK | PARP1 999/4885GRIN2B 1853/4885SLC6A2 3994/4885 |
| US-10723725-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | PARP1 999/4885GRIN2B 1853/4885SLC6A2 3994/4885 |
| US-11034685-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | PARP1 999/4885GRIN2B 1853/4885SLC6A2 3994/4885 |
| US-11034686-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | PARP1 999/4885GRIN2B 1853/4885SLC6A2 3994/4885 |
| US-10233176-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | PARP1 999/4885GRIN2B 1853/4885SLC6A2 3994/4885 |
| US-20200299288-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K6, MAP3K5, MERTK | PARP1 999/4885GRIN2B 1853/4885SLC6A2 3994/4885 |
| US-20190152965-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K6, MAP3K5, MERTK | PARP1 999/4885GRIN2B 1853/4885SLC6A2 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.